Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 233

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 233
---
s/ Kelly Stackpole                   |                      |
| Name:                                 | Kelly Stackpole      |
| Title:                                | CEO                  |

<div align='center'>SCHEDULE A – PATENT RIGHTS</div>

| Country |     | Application No. |     | Filed     |     | Title                                    |
| WO      |     | PCT/US25/17127  |     | 2/25/2025 |     | SYNTHETIC CANNABINOID ANALOGS,           
 PHARMACEUTICAL COMPOSITIONS, AND         
 METHODS OF TREATING ANXIETY AND OTHER    
 DISORDERS                                |
| US      |     | 63/653,326      |     | 5/30/2024 |     | SYNTHETIC CANNABINOID ANALOGS,           
 PHARMACEUTICAL COMPOSITIONS, AND         
 METHODS OF TREATING BACTERIAL INFECTIONS 
 AND VIRAL INFECTIONS                     |

Annex F

<div align='center'>MIRA PHARMACEUTICALS, INC.

2022 OMNIBUS INCENTIVE PLAN

(AS AMENDED AND RESTATED)</div>

1. Purposes and Effective Date.

(a) Purposes. The MIRA Pharmaceuticals, Inc. 2022 Omnibus Incentive Plan, as amended and restated, has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, directors, employees, and consultants and (ii) to increase shareholder value. The Plan will provide participants incentives to increase shareholder value by offering the opportunity to acquire shares of the Company’s common stock, receive monetary payments based on the value of such common stock, or receive other incentive compensation, on the potentially favorable terms that this Plan provides.

(b) Effective Date. The Plan originally became effective on June 15, 2022 (the “Effective Date”) and was originally adopted as the “MIRA1a Therapeutics, Inc. 2022 Omnibus Incentive Plan.” On October 6, 2022, the Company changed its corporate name to MIRA Pharmaceuticals, Inc. This amendment and restatement of the Plan was adopted and approved by the Board and stockholders of the Company effective June 27, 2023 (the “Amendment Date”) and reflects the Company’s 1-for-5 reverse stock split of its issued and outstanding common stock that became effective on June 28, 2023. This Plan will terminate as provided in